IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$15.84 USD
+3.54 (28.78%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $16.10 +0.26 (1.64%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for IGM Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 266 | 229 | 165 | 83 | 45 |
Income After Depreciation & Amortization | -263 | -228 | -165 | -83 | -45 |
Non-Operating Income | 18 | 7 | 0 | 2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -246 | -221 | -165 | -81 | -43 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -246 | -221 | -165 | -81 | -43 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -246 | -221 | -165 | -81 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -264 | -225 | -160 | -82 | -44 |
Depreciation & Amortization (Cash Flow) | -1 | 3 | 5 | 1 | 0 |
Income After Depreciation & Amortization | -263 | -228 | -165 | -83 | -45 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 52.31 | 41.54 | 33.48 | 30.75 | 9.00 |
Diluted EPS Before Non-Recurring Items | -4.71 | -5.32 | -4.93 | -2.65 | -4.80 |
Diluted Net EPS (GAAP) | -4.71 | -5.32 | -4.93 | -2.65 | -4.80 |
Fiscal Year end for IGM Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.25 | 0.50 | 0.65 | 0.51 | 0.45 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.25 | 0.50 | 0.65 | 0.51 | 0.45 |
SG&A, R&D, and Dept/Amort Expenses | 52.61 | 54.36 | 65.77 | 67.27 | 68.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | -51.36 | -53.86 | -65.12 | -66.76 | -68.20 |
Non-Operating Income | 3.46 | 4.04 | 4.67 | 5.01 | 3.89 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -47.90 | -49.82 | -60.45 | -61.75 | -64.31 |
Income Taxes | 0.00 | 0.00 | 0.24 | 0.24 | 0.11 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -47.90 | -49.82 | -60.70 | -61.99 | -64.42 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -47.90 | -49.82 | -60.70 | -61.99 | -64.42 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 60.43 | 60.11 | 59.83 | 59.58 | 45.12 |
Diluted EPS Before Non-Recurring Items | -0.79 | -0.83 | -1.01 | -1.04 | -1.43 |
Diluted Net EPS (GAAP) | -0.79 | -0.83 | -0.91 | -1.04 | -1.43 |